SET Recombinant Antibody, RBITC Conjugated
Applications
Reactivity
Predicted Reactivity
| Overview | |
| Catalog # | bsm-54264r-rbitc |
| Product Name | SET Recombinant Antibody, RBITC Conjugated |
| Applications |
WB
IF
FLOW-CYT
|
| Reactivity | Human |
| Predicted Reactivity | Mouse, Rat |
| Specifications | |
| Conjugation | RBITC |
| Host | Rabbit |
| Source | Synthetic peptide within Human SET aa 200 to the C-terminus |
| Clonality | Recombinant |
| Isotype | IgG |
| Concentration | Lot Dependent |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 6418 |
| Swiss Prot | Q01105 |
| Subcellular location | Cytoplasm, Nucleus, Endoplasmic reticulum |
| Synonyms | Protein SET; HLA-DR-associated protein II; Inhibitor of granzyme A-activated DNase, PHAPII; Phosphatase 2A inhibitor I2PP2A; Template-activating factor I; IGAAD; I-2PP2A; TAF-I. |
| Background | Multitasking protein, involved in apoptosis, transcription, nucleosome assembly and histone chaperoning. Isoform 2 anti-apoptotic activity is mediated by inhibition of the GZMA-activated DNase, NME1. In the course of cytotoxic T-lymphocyte (CTL)-induced apoptosis, GZMA cleaves SET, disrupting its binding to NME1 and releasing NME1 inhibition. Isoform 1 and isoform 2 are potent inhibitors of protein phosphatase 2A. Isoform 1 and isoform 2 inhibit EP300/CREBBP and PCAF-mediated acetylation of histones (HAT) and nucleosomes, most probably by masking the accessibility of lysines of histones to the acetylases. The predominant target for inhibition is histone H4. HAT inhibition leads to silencing of HAT-dependent transcription and prevents active demethylation of DNA. Both isoforms stimulate DNA replication of the adenovirus genome complexed with viral core proteins; however, isoform 2 specific activity is higher. |
| Application Dilution | |
| WB | 1:500-2000 |
| IF | 1:100-200 |
| Flow-Cyt | 1:50-100 |
Frequently asked questions
Which applications is SET Recombinant Antibody, RBITC Conjugated (bsm-54264R-RBITC) validated for, and at what dilution?
bsm-54264R-RBITC is validated for WB (1:500-2000); IF (1:100-200); Flow-Cyt (1:50-100). These are recommended starting dilutions; optimal dilutions should be determined by the end user.
Which species does SET Recombinant Antibody, RBITC Conjugated (bsm-54264R-RBITC) react with?
Tested reactivity: Human. Predicted reactivity (expected from sequence homology but not yet tested): Mouse, Rat.
How should bsm-54264R-RBITC be stored?
Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. Storage buffer: Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
What immunogen was used to raise SET Recombinant Antibody, RBITC Conjugated (bsm-54264R-RBITC)?
Synthetic peptide within Human SET aa 200 to the C-terminus
What are the excitation and emission wavelengths of the RBITC conjugate (bsm-54264R-RBITC)?
RBITC on bsm-54264R-RBITC: excitation / emission 570nm/595nm.